These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24772645)

  • 1. [Immunization with live attenuated A/H5N1 vaccine protects guinea pigs from reinfection].
    Sergeeva MV; Kuznetsov VV; Kas'ianenko MA; Shaldzhian AA; Repko IA; Potapchuk MV; Romanova IuR; Tsybalova LM
    Vopr Virusol; 2013; 58(6):36-9. PubMed ID: 24772645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.
    Isakova-Sivak I; Chen LM; Bourgeois M; Matsuoka Y; Voeten JT; Heldens JG; van den Bosch H; Klimov A; Rudenko L; Cox NJ; Donis RO
    Clin Vaccine Immunol; 2014 May; 21(5):722-31. PubMed ID: 24648485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Peculiarity of reassortment of current wild type influenza viruses with master donor viruses for live influenza vaccine].
    Kiseleva IV; Bazhenova EA; Larionova NV; Fedorova EA; Dubrovina IA; Isakova-Sivak IN; Rudenko LG
    Vopr Virusol; 2013; 58(5):26-31. PubMed ID: 24640168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.
    Isakova-Sivak I; de Jonge J; Smolonogina T; Rekstin A; van Amerongen G; van Dijken H; Mouthaan J; Roholl P; Kuznetsova V; Doroshenko E; Tsvetnitsky V; Rudenko L
    PLoS One; 2014; 9(7):e102339. PubMed ID: 25058039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].
    Smolonogina TA; Desheva IuA; Rekstin AR; Mironov AN; Rudenko LG
    Vopr Virusol; 2013; 58(6):31-5. PubMed ID: 24772644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets.
    Joseph T; McAuliffe J; Lu B; Vogel L; Swayne D; Jin H; Kemble G; Subbarao K
    Virology; 2008 Aug; 378(1):123-32. PubMed ID: 18585748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The inoculative properties of cold-adapted reassortant A(H5N2) influenza strain during intranasal administration to mice].
    Desheva IuA; Lu Kh; Rekstin AR; Kats DM; Rudenko LG; Klimov AI
    Vopr Virusol; 2007; 52(4):27-30. PubMed ID: 17722607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates.
    Fan S; Gao Y; Shinya K; Li CK; Li Y; Shi J; Jiang Y; Suo Y; Tong T; Zhong G; Song J; Zhang Y; Tian G; Guan Y; Xu XN; Bu Z; Kawaoka Y; Chen H
    PLoS Pathog; 2009 May; 5(5):e1000409. PubMed ID: 19412338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets.
    Chen GL; Lamirande EW; Cheng X; Torres-Velez F; Orandle M; Jin H; Kemble G; Subbarao K
    J Virol; 2014 Mar; 88(5):2867-76. PubMed ID: 24371061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
    Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).
    Rudenko L; Desheva J; Korovkin S; Mironov A; Rekstin A; Grigorieva E; Donina S; Gambaryan A; Katlinsky A
    Influenza Other Respir Viruses; 2008 Nov; 2(6):203-9. PubMed ID: 19453396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
    Kingstad-Bakke B; Kamlangdee A; Osorio JE
    Vaccine; 2015 Sep; 33(39):5155-62. PubMed ID: 26271828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
    Govorkova EA; Webby RJ; Humberd J; Seiler JP; Webster RG
    J Infect Dis; 2006 Jul; 194(2):159-67. PubMed ID: 16779721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single dose of oil-adjuvanted inactivated vaccine protects chickens from lethal infections of highly pathogenic H5N1 influenza virus.
    Hwang SD; Kim HS; Cho SW; Seo SH
    Vaccine; 2011 Mar; 29(11):2178-86. PubMed ID: 21172378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.